PapersFlow Research Brief
Histone Deacetylase Inhibitors Research
Research Guide
What is Histone Deacetylase Inhibitors Research?
Histone Deacetylase Inhibitors Research is the study of compounds that inhibit histone deacetylases (HDACs) to modulate epigenetic regulation, gene expression, cellular functions, and therapeutic applications in cancer and neurodegenerative disorders.
This field encompasses 36,720 papers examining HDACs' roles in acetylation, protein complexes, and enzymatic activity. HDAC inhibitors are investigated for cancer therapy, including glioblastoma and acute myeloid leukemia treatments. Research also addresses impacts on neurodegenerative disorders through epigenetic modifications.
Topic Hierarchy
Research Sub-Topics
HDAC Inhibitors in Cancer Epigenetic Therapy
This sub-topic investigates class I/II HDAC inhibitors like vorinostat for reactivating tumor suppressor genes via histone acetylation. Clinical trials and resistance mechanisms are key research foci in hematologic and solid malignancies.
Class-Specific Histone Deacetylase Inhibitors
Researchers develop isoform-selective inhibitors targeting HDAC1-11 classes to minimize toxicity while retaining efficacy. Structure-activity studies and selectivity profiling drive medicinal chemistry efforts.
HDACs in Gene Expression Regulation
Studies elucidate HDAC recruitment to promoters via corepressors like Sin3 and NCoR, silencing developmental and cell cycle genes. ChIP-seq and CRISPR screens map HDAC-dependent epigenomes.
HDAC Inhibitors in Neurodegenerative Diseases
This area explores HDACi neuroprotective effects in Alzheimer's, Huntington's, and Parkinson's via alpha-tubulin acetylation and autophagy induction. Preclinical models test cognitive restoration and protein aggregate clearance.
Non-Histone Protein Acetylation by HDACs
Research examines HDAC-mediated deacetylation of transcription factors (p53, FoxO), metabolic enzymes, and cytoskeletal proteins. Proteomic mapping reveals acetylation's broad regulatory scope beyond chromatin.
Why It Matters
HDAC inhibitors influence cancer therapy by altering epigenetic marks that affect gene expression and tumor progression. In glioblastoma, patients with methylated MGMT promoter benefited from temozolomide, linking epigenetic silencing to treatment outcomes (Hegi et al., 2005). The 2017 ELN recommendations for AML management incorporate advances in epigenetic therapies, reflecting HDAC-related strategies in clinical guidelines (Döhner et al., 2016). Epigenetic alterations, including those targeted by HDAC inhibitors, are ubiquitous in cancers, enabling potential therapeutic reversibility (Esteller, 2008). Lysine acetylation, regulated by HDACs, co-regulates major cellular functions via protein complexes (Choudhary et al., 2009).
Reading Guide
Where to Start
"MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma" by Hegi et al. (2005), as it provides a clear example of epigenetic modification predicting HDAC inhibitor-related therapy response in a common cancer.
Key Papers Explained
Hegi et al. (2005) "MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma" establishes epigenetic MGMT silencing's role in temozolomide response, which Stupp et al. (2009) "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma" extends to 5-year survival data. Döhner et al. (2016) "Diagnosis and management of AML in adults: 2017 ELN recommendations" builds on epigenetic principles for leukemia guidelines. Jones and Baylin (2007) "The Epigenomics of Cancer" and Esteller (2008) "Epigenetics in Cancer" provide foundational overviews of HDAC-related epigenomics, while Choudhary et al. (2009) "Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions" details molecular mechanisms.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues to explore HDAC inhibitors' integration into glioblastoma protocols post-Stupp et al. (2009) and AML guidelines from Döhner et al. (2016), focusing on combination with temozolomide for MGMT-stratified patients. No recent preprints or news available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Effects of radiotherapy with concomitant and adjuvant temozolo... | 2009 | The Lancet Oncology | 7.6K | ✕ |
| 2 | <i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Gl... | 2005 | New England Journal of... | 7.1K | ✓ |
| 3 | Diagnosis and management of AML in adults: 2017 ELN recommenda... | 2016 | Blood | 5.7K | ✓ |
| 4 | The Epigenomics of Cancer | 2007 | Cell | 4.4K | ✓ |
| 5 | A simple method for clinical assay of superoxide dismutase. | 1988 | Clinical Chemistry | 4.3K | ✕ |
| 6 | Cancer Metastasis: Building a Framework | 2006 | Cell | 4.2K | ✓ |
| 7 | Malignant Gliomas in Adults | 2008 | New England Journal of... | 4.2K | ✕ |
| 8 | Selective inhibition of BET bromodomains | 2010 | Nature | 4.2K | ✓ |
| 9 | Lysine Acetylation Targets Protein Complexes and Co-Regulates ... | 2009 | Science | 4.0K | ✕ |
| 10 | Epigenetics in Cancer | 2008 | New England Journal of... | 3.6K | ✓ |
Frequently Asked Questions
What role do HDAC inhibitors play in glioblastoma treatment?
Temozolomide combined with radiotherapy improves survival in glioblastoma, with greater benefit in patients having methylated MGMT promoter, an epigenetic modification influenced by HDAC activity (Stupp et al., 2009; Hegi et al., 2005). MGMT silencing enhances temozolomide efficacy by preventing DNA repair. This underscores HDAC inhibitors' potential in epigenetically sensitized therapies.
How are HDAC inhibitors relevant to acute myeloid leukemia?
The 2017 ELN recommendations for AML diagnosis and management highlight recent advances in epigenetic discoveries, including HDAC inhibition (Döhner et al., 2016). These build on prior guidelines to incorporate targeted therapies. HDAC inhibitors address aberrant gene expression in leukemia cells.
What is the connection between lysine acetylation and HDACs?
Lysine acetylation targets protein complexes and co-regulates cellular functions, with HDACs removing acetyl groups to control activity (Choudhary et al., 2009). This modification is prevalent and dynamically regulates enzymatic processes. HDAC inhibitors disrupt this balance for therapeutic effects.
Why are epigenetic changes significant in cancer?
Epigenetic alterations like those in DNA methylation and histone acetylation are common in cancers and can be reversed by HDAC inhibitors (Jones and Baylin, 2007; Esteller, 2008). These changes affect gene expression without altering DNA sequence. Targeting HDACs offers strategies to restore normal regulation.
What cellular functions do HDACs regulate?
HDACs regulate gene expression, cellular functions, and epigenetic modifications through deacetylation in protein complexes (Choudhary et al., 2009). They impact cancer therapy and neurodegenerative disorders. Inhibitors alter these processes to influence disease states.
Open Research Questions
- ? How do specific HDAC inhibitors synergize with temozolomide in MGMT-methylated versus unmethylated glioblastomas?
- ? What are the precise mechanisms by which HDAC inhibition affects AML subtypes beyond current ELN recommendations?
- ? In which protein complexes does lysine acetylation by HDACs most critically drive metastatic potential in solid tumors?
- ? Can HDAC inhibitors reverse epigenetic changes in neurodegenerative disorders as effectively as in cancer?
- ? How do HDAC inhibitors interact with BET bromodomain inhibitors to modulate shared epigenetic targets?
Recent Trends
The field includes 36,720 works with established high-citation papers like Stupp et al. (2009, 7649 citations) and Hegi et al. (2005, 7066 citations) on glioblastoma epigenetics, alongside Döhner et al. (2016, 5711 citations) for AML. No growth rate data, recent preprints, or news reported in the last 12 months.
Research Histone Deacetylase Inhibitors Research with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Histone Deacetylase Inhibitors Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers